With a new year on the horizon, what better time to refresh a portfolio.
But which ASX 200 shares would be worthy of a spot in your portfolio in 2023? Three that analysts at Bell Potter rate highly are listed below.
Here's what they are saying about these ASX 200 shares:
CSL Limited (ASX: CSL)
The first ASX 200 share that Bell Potter rates highly is CSL. Its analysts like the biotherapeutics company due to growing plasma volumes, new product launches, and its recent acquisition. It notes that the Vifor Pharma acquisition has added global leadership in renal disease and iron deficiency. The broker commented:
The recently completed acquisition of Vifor Pharma will add global leadership in pharmaceutical products for renal disease and iron deficiency. The global growth in plasma volumes is expected to be around a solid 8% per annum for the foreseeable future and, in addition, the group is planning to launch new products from its very extensive Research and Development portfolio.
Goodman Group (ASX: GMG)
Another ASX share that Bell Potter rates highly is this integrated industrial property company. Its analysts are expecting Goodman's shares to be strong performers over the coming years thanks to robust demand for industrial property due partly to the rise of online shopping. It commented:
One of the world's largest integrated industrial property groups with operations centred around development, management and ownership throughout Australia, New Zealand, Asia, Europe, United Kingdom, North America, and Brazil. The long term outlook for industrial and logistics properties is favourable given the continuing growth in ecommerce (or on-line retail sales) and the growing middle class in developing countries.
Sonic Healthcare Limited (ASX: SHL)
Finally, Bell Potter thinks this medical diagnostic services provider is an ASX 200 share to buy. The broker believes Sonic is well-placed to benefit from demand for pathology services and its ongoing international expansion. It commented:
The world's third largest pathology provider with significant operations in the USA, United Kingdom, Germany, Switzerland, Belgium, Australia and New Zealand. Against the backdrop of continuing growth in the demand for pathology services over the longer term, the group has further international expansion opportunities in both existing and new geographical markets.
